Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

William J. Gradishar, MD, on HER2-Negative Breast Cancer: The Treatment Pipeline

Posted: Thursday, March 21, 2019

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the top prospects in targeted therapy now under study for advanced-stage HER2-negative breast cancer, and how close they are to being used in the clinic.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.